



Docket No. RT 474

TECH CENTER 1600/2900

MAR 13 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Richard Apodaca et al.

Serial No. : 09/922,619

Art Unit: 1626

Filed : August 6, 2001

Examiner: Wright, Sonya N.

For : NON-IMIDAZOLE ARYLOXYPIPERIDINES

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner for Patents, Washington, D.C. 20231

March 1, 2002

(Date)

Evelyn D. Shen

Name of applicant, assignee, or Registered Representative

(Signature)

March 1, 2002

(Date of Signature)

Commissioner for Patents
Washington, D.C. 20231

RESPONSE

Restriction Requirement Under 35 U.S.C. 121

Dear Sir:

In response to the Official communication mailed on February 1, 2002, relating to the above patent application, Applicants elect Group II, Claims 1-60, drawn to compounds and methods of use wherein G or W is piperazine and morpholine, classified in class

#5
AKO
3.23.02

544, subclass 63. Applicants respectfully request that the Examiner consider including G or W is L₂Q within this Group II.

If the Examiner would like to discuss the above, she is invited to contact the undersigned at any time. Applicants respectfully traverse this restriction requirement.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read 'E. Shen', written over a horizontal line.

Evelyn D. Shen
Reg. No. 39,834
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
(732) 524-6040